Creo Medical Group plc
("Creo" or the "Company")
Award of Shares under Share Incentive Plan, Director Dealings and Issue of Equity
As detailed in the Company's Annual Report for the year ended 31 December 2020 the Company implemented an HMRC approved Share Incentive Plan ("SIP") during 2020 which is available to all of the Company's UK based employees, including Directors.
Under the SIP, shares are acquired in four ways:
· Partnership Shares where an employee can spend up to a £1,800 or 10% of their pre-tax income, whichever is the lower;
· Matching Shares, where Creo can give up to two free Matching Shares for each Partnership Share bought. The plan requires employees to remain in employment for three years to benefit from the Matching Shares;
· Free Shares, where Creo can give up to £3,600 of free shares in any tax year; and
· Dividend Shares where additional shares can be bought with any dividends paid.
On 19 July 2021, the Company was notified that Yorkshire Building Society, the independent trustee of the SIP, had acquired, in accordance with the SIP's rules and on behalf of SIP participants, 30,806 ordinary shares in the Company ("Ordinary Shares"), at a price of £1.7984 pence per Ordinary Share to meet its obligations under the SIP. Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased, being 61,612 new Ordinary Shares. These new Ordinary Shares will be held by Yorkshire Building Society as trustee of the SIP.
Craig Gulliford and Richard Rees, executive directors of the Company (the "Participating Directors") have received Partnership Shares at a price of £1.7984 per share and Matching shares at a price of £0.001 per share in accordance with terms of the SIP. Following this the Participating Directors' shareholdings in the Company are as set out in the table below:
| Director | Number of Ordinary Shares awarded under SIP | Total number of Ordinary Shares held post transaction |
| Craig Gulliford, CEO | 1,500 | 611,386 |
| Richard Rees, CFO | 1,500 | 1,500 |
Accordingly, the Company announces that it has made an application for 61,612 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 26 July 2021. Following the allotment and issue, the Company's issued share capital consists of 161,002,002 Ordinary Shares. The Company does not hold any shares in Treasury. As such the total number of shares in issue with voting rights is 161,002,002.
The above figure of 161,002,002 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.
Enquires:
| Creo Medical Group plc | |
| Richard Rees (CFO) | +44 (0)1291 606 005 |
|
|
|
| Cenkos Securities plc | +44 (0)20 7397 8900 |
| Stephen Keys / Camilla Hume (NOMAD) |
|
| Michael Johnson / Russell Kerr (Sales) |
|
|
|
|
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
| Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed the CROMA Advanced Energy Platform powered by Kamaptive™ full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive™ is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive™ technology provides clinicians with increased flexibility, precision and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by Kamaptive™ technology to market, enabling a wide range of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy Platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com
| 1. Details of PDMR | ||||||||
| a) | Name | Craig Gulliford | ||||||
| b) | Position / status | CEO | ||||||
| c) | Initial notification / amendment | Initial notification | ||||||
| 2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
| a) | Description of the financial instrument | Ordinary Shares | ||||||
| b) | Nature of the transaction | Award of Ordinary Shares under Share Incentive Plan
| ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information
Aggregated volume Price | 1,500 Ordinary Shares @ Weighted Average Price of £0.6001
| ||||||
| e) | Date of the transaction | 2021-07-26 GMT | ||||||
| f) | Place of the transaction | London Stock Exchange | ||||||
| 1. Details of PDMR | ||||||||
| a) | Name | Richard Rees | ||||||
| b) | Position / status | CFO | ||||||
| c) | Initial notification / amendment | Initial notification | ||||||
| 2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
| a) | Description of the financial instrument | Ordinary Shares | ||||||
| b) | Nature of the transaction | Award of Ordinary Shares under Share Incentive Plan
| ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information
Aggregated volume Price | 1,500 Ordinary Shares @ Weighted Average Price of £0.6001
| ||||||
| e) | Date of the transaction | 2021-07-26 GMT | ||||||
| f) | Place of the transaction | London Stock Exchange | ||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
